Visfatin/eNAMPT (NAMPT): Extracellular Nicotinamide Phosphoribosyltransferase as Adipokine, NAD+ Regulator, and Cancer Driver in Research

# Visfatin/eNAMPT (NAMPT): Extracellular Nicotinamide Phosphoribosyltransferase as Adipokine, NAD+ Regulator, and Cancer Driver in Research

Visfatin/eNAMPT occupies a unique position in the history of adipokine research — initially celebrated as a promising insulin-mimetic adipokine, then embroiled in a high-profile replication controversy, and ultimately vindicated as a genuinely important biological molecule whose true significance lay in a completely different mechanism than originally proposed. The protein is encoded by the NAMPT gene and functions intracellularly as the rate-limiting enzyme in the NAD+ salvage biosynthesis pathway. Its extracellular form (eNAMPT), secreted unconventionally through a non-classical pathway, acts as a systemic signaling molecule with roles in aging, cancer, inflammation, and metabolic regulation that are entirely distinct from its enzymatic activity.

Discovery, Naming Confusion, and the Replication Crisis

The protein now known as NAMPT has a complex nomenclatural history that reflects its discovery by multiple groups in different contexts. The gene product was first identified in 1994 by Samal et al. as PBEF (Pre-B cell colony-Enhancing Factor), a secreted factor that synergized with IL-7 and stem cell factor to enhance pre-B cell colony formation in a bone marrow stromal cell co-culture system. The factor was shown to be produced by activated lymphocytes and to have cytokine-like activity.

The insulin receptor activation claim, in retrospect, likely arose from a technical artifact related to recombinant protein preparation (possible endotoxin contamination triggering non-specific signaling, or contaminating growth factors in cell culture reagents). The protein does not appear to activate the insulin receptor at physiologically relevant concentrations in properly controlled experiments.

Despite the retraction controversy, subsequent research has established NAMPT/eNAMPT as genuinely biologically important — just through entirely different mechanisms than originally proposed.

Gene Structure and Protein Biology

Nicotinamide + PRPP → Nicotinamide mononucleotide (NMN) + PPi

The product NMN is then converted to NAD+ by nicotinamide mononucleotide adenylyltransferases (NMNAT1-3), completing the two-step salvage pathway. Because most mammalian cells lack the de novo synthesis pathway from tryptophan at high capacity, the NAMPT-catalyzed step is rate-limiting for maintaining cellular NAD+ concentrations.

NAMPT lacks a classical signal peptide or transmembrane domain, yet significant amounts are found in the extracellular space (plasma concentrations: 1-10 nM in humans). The secretion mechanism is non-classical — vesicular and non-vesicular pathways have both been described, including secretion in exosomes/extracellular vesicles and through an unconventional ATP-binding cassette (ABC) transporter-dependent mechanism. Interestingly, secreted eNAMPT retains enzymatic activity and can catalyze NMN production in the extracellular space, potentially generating a local NMN pool for cellular uptake.

A post-translational modification unique among known enzymes is the phosphorylation of NAMPT at Ser313 by non-receptor tyrosine kinase pathways; this phosphorylation event enhances enzymatic activity approximately 2-fold and is implicated in the regulation of NAMPT activity during cell stress.

Intracellular NAMPT (iNAMPT): NAD+ Biosynthesis and Cellular Metabolism

The intracellular function of NAMPT — maintaining cellular NAD+ levels — underlies virtually all of its downstream biological effects, since NAD+ is an essential cofactor and substrate for:

• •Sirtuins (SIRT1-7): NAD+-dependent deacylases that regulate gene expression, metabolism, DNA repair, and aging
• •PARP1/2 (poly-ADP ribose polymerases): Consume NAD+ in DNA damage response; PARP1 alone can deplete cellular NAD+ during intense DNA damage
• •CD38 and CD157: NAD+ glycohydrolases that generate cyclic ADP-ribose (cADPR) and ADPR for Ca²⁺ signaling
• •Complex I: While not a direct NAD+ consumer, mitochondrial NADH production requires adequate NAD+ substrate supply

By controlling NAD+ availability, NAMPT acts as a master metabolic regulator:

NAMPT-SIRT1 Axis and Circadian Clock

This circuit connects nutritional status (NAD+ precursor availability) to circadian timing, providing a molecular mechanism for how fasting, caloric restriction, and dietary NAD+ precursors (nicotinamide riboside, NMN) synchronize metabolism with the biological clock.

NAMPT and Aging

NAD+ levels decline with age in multiple tissues, and this decline has been causally linked to age-associated metabolic dysfunction. The decline reflects reduced NAMPT activity, increased CD38-mediated NAD+ consumption, and possibly reduced substrate availability. Key evidence:

• •Germline deletion of NAMPT in specific cell types (β-cells, skeletal muscle, hepatocytes, neurons) produces phenotypes resembling accelerated aging in the affected tissue
• •Pharmacological NAMPT inhibition in rodents causes rapid NAD+ depletion and metabolic deterioration
• •Circulating eNAMPT levels decline with age in mice, and restoration of eNAMPT to youthful levels extends healthspan (Yoshida et al., 2019, Nat Metab — a study with significant caveats but generating substantial interest)

The aging biology of NAMPT has driven significant interest in NAD+ precursor supplementation (NR, NMN) as a longevity-adjacent intervention, though human clinical data remain preliminary.

Extracellular NAMPT (eNAMPT): Systemic Signaling

Sources and Regulation of eNAMPT Secretion

Multiple cell types secrete eNAMPT, with adipocytes (particularly visceral adipocytes) being the most abundant source in terms of circulating contributions, consistent with the original "visfatin" observations. Additional major sources include:

• •Activated macrophages and monocytes
• •Hepatocytes (released during liver stress)
• •Endothelial cells
• •Skeletal muscle cells (in response to exercise)
• •Tumor cells (many cancer types overexpress and secrete NAMPT)

Plasma eNAMPT levels are regulated by nutritional status: fasting reduces eNAMPT (reducing NAD+ demand in circulating cells), while high-fat feeding and obesity increase eNAMPT. Inflammatory signals (LPS, TNF-α, IL-1β) strongly upregulate both intracellular NAMPT expression and eNAMPT secretion from multiple cell types.

eNAMPT as a Cytokine-like Signaling Molecule

Independent of its enzymatic activity, eNAMPT has been shown to activate TLR4 (Toll-like receptor 4) in multiple studies. eNAMPT binding to TLR4 triggers NF-κB activation, inflammatory cytokine production (IL-6, TNF-α, IL-1β), and neutrophil degranulation. This TLR4-mediated inflammatory activity is non-enzymatic — catalytically dead NAMPT mutants retain TLR4 activation capacity — suggesting that eNAMPT acts as an endogenous TLR4 ligand (a DAMP-like activity).

The TLR4 activation mechanism positions eNAMPT as a "sterile inflammation" mediator: released from damaged or stressed cells (particularly adipocytes in obesity), it activates innate immune cells to produce inflammatory cytokines without a microbial trigger, contributing to obesity-associated chronic low-grade inflammation.

eNAMPT-TLR4 in Acute Inflammation and Organ Injury

Beyond metabolic inflammation, eNAMPT has been extensively studied in acute inflammatory conditions:

Acute lung injury (ALI/ARDS): Plasma and bronchoalveolar lavage fluid eNAMPT is dramatically elevated in ALI/ARDS patients, and elevated eNAMPT predicts disease severity and mortality. In mouse models of LPS-induced ALI, NAMPT heterozygous mice (lower NAMPT expression) show reduced lung injury, while eNAMPT administration worsens lung injury through TLR4.

Sepsis: eNAMPT serves as a biomarker of sepsis severity; levels above 50 ng/mL in the context of SIRS criteria correlate with increased risk of organ failure. Anti-NAMPT antibodies reduce organ injury in cecal ligation and puncture (CLP) sepsis models.

Ischemia-reperfusion: eNAMPT released from ischemic tissue activates TLR4 on infiltrating immune cells, amplifying post-ischemic inflammation.

Cancer Biology

The cancer biology of NAMPT has emerged as perhaps its most clinically actionable area. Multiple mechanisms link NAMPT to malignancy:

NAD+ Demand in Cancer

Rapidly proliferating cancer cells have exceptionally high NAD+ demand due to:

1. Enhanced PARP activity for DNA repair (addressing replication stress)

2. Sirtuin activity for epigenetic reprogramming

3. NAD+ as a glycolysis co-factor supporting the Warburg effect (aerobic glycolysis)

4. Increased biomass production requiring NADPH (from NAD+)

This high demand makes cancer cells exquisitely sensitive to NAMPT inhibition. Cancer cells with compromised de novo NAD+ synthesis pathways (deficient NAPRT expression, which would otherwise allow rescue) are predicted to be most sensitive to NAMPT inhibition.

NAMPT Overexpression in Cancer

NAMPT is overexpressed at the mRNA and protein level in multiple cancer types including colorectal cancer, breast cancer, gastric cancer, non-Hodgkin lymphoma, glioblastoma, and others. Elevated tumor NAMPT expression correlates with worse prognosis in several cohorts. eNAMPT secreted by tumor cells and tumor-associated macrophages creates a pro-tumorigenic, pro-inflammatory microenvironment.

NAMPT Inhibitors as Anti-Cancer Agents

The clinical development of NAMPT inhibitors has been a major focus:

FK866 (APO866): The first potent and selective NAMPT inhibitor (Ki ~0.1 nM), FK866 depletes cellular NAD+ and induces apoptosis in cancer cells in vitro at nanomolar concentrations. Phase I clinical trials (2005-2010) showed dose-limiting thrombocytopenia (platelets are highly dependent on NAMPT) as the primary toxicity. The therapeutic window was narrow, limiting monotherapy efficacy.

GMX1778 (CHS-828): A second NAMPT inhibitor with similar mechanism, also evaluated in Phase I trials with comparable tolerability issues.

NAMPT inhibitor combinations: Rational combinations with DNA damage response inhibitors (PARP inhibitors, ATR inhibitors) exploit synthetic lethality in NAMPT-depleted, replication-stressed cancer cells. Early data suggest improved anti-tumor efficacy at lower doses.

Biomarker-selected populations: Tumors with low NAPRT expression (unable to rescue NAD+ through the NAPRT pathway) are predicted to be maximally sensitive. NAPRT IHC staining has been proposed as a patient selection biomarker.

eNAMPT as cancer biomarker: Plasma eNAMPT is elevated in multiple cancer types and correlates with tumor burden in some studies, suggesting potential as a liquid biopsy marker, though specificity issues (eNAMPT is elevated in inflammatory conditions generally) limit clinical utility.

Metabolic Functions Beyond Visceral Fat

Despite the retraction of the insulin receptor activation claim, eNAMPT does modulate glucose metabolism through indirect mechanisms:

• •Pancreatic β-cells: NAMPT is highly expressed in β-cells and essential for maintaining NAD+ → SIRT1 → insulin secretion coupling. β-cell-specific NAMPT deletion impairs GSIS and leads to diabetes in mice.
• •Skeletal muscle: Exercise-induced eNAMPT secretion from muscle delivers NMN precursor to adjacent cells, potentially supporting post-exercise NAD+ restoration.
• •Liver: Hepatic NAMPT regulates SIRT1-mediated deacetylation of PGC-1α, modulating gluconeogenesis and fatty acid oxidation. Hepatocyte-specific NAMPT deletion impairs mitochondrial function and promotes hepatic steatosis.
• •Adipose tissue inflammation: eNAMPT from hypertrophied adipocytes activates TLR4 on macrophages, promoting M1 polarization and pro-inflammatory cytokine production in obese adipose tissue — a mechanism independent of insulin receptor signaling but contributing to insulin resistance.

Research Tools and Experimental Systems

Current Research Frontiers

NMN/NR supplementation and human aging: Multiple Phase I/II clinical trials of NMN and nicotinamide riboside (NR) have demonstrated safety and dose-dependent NAD+ increases in human tissues. Whether NAD+ repletion translates to clinically meaningful health benefits remains under investigation in larger Phase II/III trials.

NAMPT inhibitor combinations in oncology: Second-generation NAMPT inhibitors with improved therapeutic windows, and rational combinations with DNA damage response pathway inhibitors, are in active clinical development. Phase I/II trials are evaluating FK866 analogs and novel NAMPT inhibitors in hematological malignancies and solid tumors with NAPRT-low status.

eNAMPT in critical illness: As a mediator of organ injury in sepsis and ARDS, eNAMPT antibody therapy (ALT-100/izokibep in preclinical stages) is being evaluated as a potential treatment for ICU patients.

Circadian NAD+ biology: The NAMPT-SIRT1-CLOCK circuit is being studied as a target for jet lag, shift work metabolic syndrome, and metabolic reprogramming. NAD+ precursors timed to circadian phase may have enhanced metabolic benefits.

Tumor immunology: The immunomodulatory effects of NAMPT on tumor-infiltrating immune cells are complex — NAMPT inhibition affects both cancer cells and immune cells (T cells have high NAD+ demand for activation and proliferation). Understanding the net immunological effect of NAMPT inhibition is essential for rational combination with checkpoint immunotherapy.

Conclusion

The NAMPT/eNAMPT story is one of the most instructive in adipokine biology — a protein whose initial characterization was largely incorrect, yet whose actual biology turned out to be far richer and more consequential. As the rate-limiting enzyme in the NAD+ salvage pathway, intracellular NAMPT governs cellular energetics, sirtuin activity, DNA repair, and circadian rhythmicity. As the extracellular cytokine eNAMPT, it acts as an adipose-derived DAMP that activates TLR4-mediated inflammation, links visceral adiposity to systemic low-grade inflammation, and promotes cancer cell survival through NAD+ supply. The drug development landscape has validated NAMPT as a cancer target (NAMPT inhibitors FK866, GMX1778) while revealing the challenge of achieving a therapeutic window in rapidly dividing normal cells. The aging biology angle, connecting NAMPT-maintained NAD+ levels to sirtuin activity and healthspan, has spawned a growing nutraceutical industry around NMN and NR supplementation. FK866, GMX1778, and recombinant eNAMPT remain the primary research tools for in vitro pharmacology; cell type-specific conditional knockout mice are the definitive in vivo models.

Key References

5. Nakahata Y, Sahar S, Astarita G, et al. Circadian control of the NAD+ salvage pathway by CLOCK-SIRT1. Science. 2009;324(5927):654-657. PMID: 19286518

---

References

• •PMID: 42698301
• •PMID: 42639858
• •PMID: 42620342

This article is intended for Research Use Only (RUO). The information provided describes laboratory research findings and does not constitute medical advice. NAMPT inhibitors (FK866, GMX1778) and related compounds are research tools and investigational agents. All research applications must comply with applicable institutional, local, and national regulations.